×
About 3,385 results

ALLMedicine™ Hypophosphatemia Center

Research & Reviews  951 results

Intracardiac thrombosis following intravenous zoledronate treatment in a child with ste...
https://doi.org/10.1515/jpem-2022-0475
Journal of Pediatric Endocrinology & Metabolism : JPEM; Case SJ, Moon RJ et. al.

Nov 26th, 2022 - Bisphosphonates are used in childhood osteoporosis but can cause an acute phase reaction (APR) and hypocalcemia. We present a child with cardiac thrombosis following zoledronate, a previously unreported complication. An 11-year-old with Duchenne m...

Severe hypophosphatemia as the initial presentation of renal Fanconi's syndrome and dis...
https://doi.org/10.1159/000527931
Kidney & Blood Pressure Research; Wu Y, Ma T et. al.

Nov 23rd, 2022 - Zoledronic acid (ZA) is a widely used bisphosphonate compound for the prevention of skeletal metastasis-associated osteolysis and treatment of post-menopause osteoporosis. Acute kidney injury is one of the commonly described renal complications. E...

New treatments for rare bone diseases: hypophosphatemic rickets/osteomalacia.
https://doi.org/10.20945/2359-3997000000555
Archives of Endocrinology and Metabolism; Marques JVO, Moreira CA et. al.

Nov 17th, 2022 - Phosphorus is one of the most abundant minerals in the human body; it is required to maintain bone integrity and mineralization, in addition to other biological processes. Phosphorus is regulated by parathyroid hormone, 1,25-dihydroxyvitamin D3 [1...

Growth pattern in children with X-linked hypophosphatemia treated with burosumab and gr...
https://doi.org/10.1186/s13023-022-02562-9
Orphanet Journal of Rare Diseases; Ertl DA, Le Lorier J et. al.

Nov 13th, 2022 - X-linked hypophosphatemia (XLH) is characterized by increased serum concentrations of fibroblast growth factor 23 (FGF23), hypophosphatemia and insufficient endogenous synthesis of calcitriol. Beside rickets, odonto- and osteomalacia, disproportio...

Rare PHEX intron variant causes complete and severe phenotype in a family with hypophos...
https://doi.org/10.1515/jpem-2022-0365
Journal of Pediatric Endocrinology & Metabolism : JPEM; Aiello F, Pasquali D et. al.

Nov 10th, 2022 - Lower limb deformities in children need careful orthopedic evaluation to distinguish physiological forms from pathological ones. X-linked hypophosphatemia (XLH) is a rare hereditary condition caused by PHEX gene mutations where tibial varum can be...

see more →

Guidelines  1 results

Refeeding Hypophosphatemia in Hospitalized Adolescents With Anorexia Nervosa.
https://doi.org/10.1016/j.jadohealth.2022.06.025
The Journal of Adolescent Health : Official Publication O...

Sep 20th, 2022 - Refeeding hypophosphatemia in hospitalized adolescents with anorexia nervosa is correlated with degree of malnutrition, with a high index of suspicion for severely malnourished patients (<70% median body mass index). Weight history (greater magnit...

see more →

Drugs  107 results see all →

Clinicaltrials.gov  74 results

Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia
https://clinicaltrials.gov/ct2/show/NCT05509595

Oct 14th, 2022 - Study Description: This will be a phase 2, open-label, single-arm study to evaluate the safety and efficacy of burosumab to normalize serum phosphate levels in subjects with fibrous dysplasia (FD) and fibroblast growth factor 23 (FGF23)-mediated h...

Examining the Effect of Burosumab on Muscle Function
https://clinicaltrials.gov/ct2/show/NCT04146935

Oct 10th, 2022 - X-linked hypophosphatemia is a skeletal dysplasia. The mineralized tissue complications of XLH have been the focus of investigative studies seeking to understand its pathogenesis, as well as studies directed at new therapies. However, in addition ...

A Trial to Assess the Safety and Efficacy of KRN23 in Epidermal Nevus Syndrome (ENS)
https://clinicaltrials.gov/ct2/show/NCT04320316

Oct 7th, 2022 - KRN23 is a fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds to and inhibits the activity of fibroblast growth factor 23 (FGF23), leading to an increase in serum phosphorus levels. There are multiple disorders (each with a ...

Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age
https://clinicaltrials.gov/ct2/show/NCT04188964

Oct 5th, 2022 - BUR-CL207 is a multicenter, open-label, non-randomized Phase 1/2 study in pediatric patients with XLH initiating treatment with burosumab at <12 months of age. The study includes a total treatment period of up to 48 weeks across 3 cohorts. Subject...

X-linked Hypophosphatemia Disease Monitoring Program
https://clinicaltrials.gov/ct2/show/NCT03651505

Oct 3rd, 2022 - The XLH-DMP is a global, prospective, multicenter, longitudinal, long-term outcomes program for subjects on or off any treatment designed to characterize XLH disease presentation and progression, assess long-term safety and effectiveness of burosu...

see more →

News  220 results

Electrolyte Disturbances a Harbinger of Eating Disorders?
https://www.medscape.com/viewarticle/984087

Nov 15th, 2022 - Electrolyte abnormalities may serve as a precursor to a future eating disorder diagnosis, a finding that may help pinpoint candidates for screening. Researchers found that adolescents and adults with electrolyte abnormalities on routine outpatient...

Telisotuzumab Vedotin Plus Erlotinib Shows Encouraging Activity in Advanced c-Met+ NSCLC
https://www.onclive.com/view/telisotuzumab-vedotin-plus-erlotinib-shows-encouraging-activity-in-advanced-c-met-nsclc

Nov 1st, 2022 - Telisotuzumab vedotin (teliso-V) in combination with erlotinib (Tarceva) induced promising outcomes in patients with advanced, EGFR-mutated, c-MET-positive non–small cell lung cancer (NSCLC) who were contraindicated for surgery or other approved t...

Cracking the “MGUS” Code Reveals Monoclonal Gammopathy of Clinical Significance:
https://www.onclive.com/view/cracking-the-mgus-code-reveals-monoclonal-gammopathy-of-clinical-significance-

Nov 1st, 2022 - When assessing monoclonal gammopathy it is important to rule out clinically significant associations requiring treatment. On initial patient consultation, gathering a detailed patient history and thorough physical exam can catch clinically signifi...

Emavusertib Is Active in Heavily Pretreated AML and High-Risk MDS With Targeted Mutations
https://www.onclive.com/view/emavusertib-is-active-in-heavily-pretreated-aml-and-high-risk-mds-with-targeted-mutations

Oct 24th, 2022 - Emavusertib (CA-4948) elicited antitumor activity when given as a monotherapy in patients with relapsed/refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS) that harbored a spliceosome or FLT3 mutation, according ...

Quizartinib Triplet Shows Activity in Heavily Pretreated, FLT3-ITD–Mutated AML
https://www.onclive.com/view/quizartinib-triplet-shows-activity-in-heavily-pretreated-flt3-itd-mutated-aml

Sep 29th, 2022 - The triplet combination regimen comprised of quizartinib, decitabine, and venetoclax (Venclexta) elicited encouraging responses in heavily pretreated patients with relapsed/refractory FLT3-ITD–mutated acute myeloid leukemia (AML) who were previous...

see more →

Patient Education  1 results see all →